These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28211602)

  • 41. Pure akinesia due to lewy body Parkinson's disease: a case with pathology.
    Quinn NP; Luthert P; Honavar M; Marsden CD
    Mov Disord; 1989; 4(1):85-9. PubMed ID: 2538728
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Extracellular α-synuclein--a possible initiator of inflammation in Parkinson's disease.
    Ren WQ; Tian ZM; Yin F; Sun JZ; Zhang JN
    Pharmazie; 2016 Feb; 71(2):51-5. PubMed ID: 27004367
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Update on the pathophysiology of Parkinson' disease].
    Duyckaerts C; Sazdovitch V; Seilhean D
    Bull Acad Natl Med; 2010 Oct; 194(7):1287-303; discussion 1303-4. PubMed ID: 22043625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PLA2G6 accumulates in Lewy bodies in PARK14 and idiopathic Parkinson's disease.
    Miki Y; Tanji K; Mori F; Kakita A; Takahashi H; Wakabayashi K
    Neurosci Lett; 2017 Apr; 645():40-45. PubMed ID: 28213071
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological roles of α-synuclein in neurological disorders.
    Vekrellis K; Xilouri M; Emmanouilidou E; Rideout HJ; Stefanis L
    Lancet Neurol; 2011 Nov; 10(11):1015-25. PubMed ID: 22014436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Substantia nigra echogenicity and imaging of striatal dopamine transporters in Parkinson's disease: a cross-sectional study.
    Bor-Seng-Shu E; Pedroso JL; Felicio AC; de Andrade DC; Teixeira MJ; Braga-Neto P; Batista IR; Barsottini OG; Borges V; Ferraz HB; Shih MC; Bressan RA; de Andrade LA; Walter U
    Parkinsonism Relat Disord; 2014 May; 20(5):477-81. PubMed ID: 24629800
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The mechanism of Lewy body formation in Parkinson's disease].
    Wakabayashi K; Takahashi H
    Nihon Rinsho; 2000 Oct; 58(10):2022-7. PubMed ID: 11068441
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autopsy follow-up of a patient with schizophrenia and presumed idiopathic Parkinson's disease.
    Friedman JH; Fernandez HH
    Clin Neuropharmacol; 2001; 24(2):120-1. PubMed ID: 11307051
    [No Abstract]   [Full Text] [Related]  

  • 49. Staging of alpha-synuclein in the olfactory bulb in a model of Parkinson's disease: cell types involved.
    Ubeda-Bañon I; Saiz-Sanchez D; de la Rosa-Prieto C; Mohedano-Moriano A; Fradejas N; Calvo S; Argandoña-Palacios L; Garcia-Muñozguren S; Martinez-Marcos A
    Mov Disord; 2010 Aug; 25(11):1701-7. PubMed ID: 20574962
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Morphological alterations of the synapses in the locus coeruleus in Parkinson's disease.
    Baloyannis SJ; Costa V; Baloyannis IS
    J Neurol Sci; 2006 Oct; 248(1-2):35-41. PubMed ID: 16753180
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Two hundred steps.
    Drew L
    Nature; 2016 Oct; 538(7626):S2-S3. PubMed ID: 27783577
    [No Abstract]   [Full Text] [Related]  

  • 54. Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.
    Yamamoto S; Fukae J; Mori H; Mizuno Y; Hattori N
    Neurosci Lett; 2006 Apr; 396(3):187-91. PubMed ID: 16386370
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Higher vulnerability and stress sensitivity of neuronal precursor cells carrying an alpha-synuclein gene triplication.
    Flierl A; Oliveira LM; Falomir-Lockhart LJ; Mak SK; Hesley J; Soldner F; Arndt-Jovin DJ; Jaenisch R; Langston JW; Jovin TM; Schüle B
    PLoS One; 2014; 9(11):e112413. PubMed ID: 25390032
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nexus between mitochondrial function, iron, copper and glutathione in Parkinson's disease.
    Liddell JR; White AR
    Neurochem Int; 2018 Jul; 117():126-138. PubMed ID: 28577988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
    Kovacs GG; Milenkovic IJ; Preusser M; Budka H
    Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
    Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
    Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity.
    Aarsland D; Londos E; Ballard C
    Int Psychogeriatr; 2009 Apr; 21(2):216-9. PubMed ID: 19173762
    [No Abstract]   [Full Text] [Related]  

  • 60. Dementia in Parkinson's disease. Morphometric data.
    Duyckaerts C; Gaspar P; Costa C; Bonnet AM; Hauw JJ
    Adv Neurol; 1993; 60():447-55. PubMed ID: 8420169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.